Madrigal Pharmaceuticals, Inc. (MDGL)
476.91
+9.63
(+2.06%)
USD |
NASDAQ |
Jun 09, 15:51
Madrigal Pharmaceuticals SG&A Expense (Quarterly) : 268.52M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Insmed, Inc. | 247.26M |
| PTC Therapeutics, Inc. | 86.18M |
| Protagonist Therapeutics, Inc. | 13.28M |
| Exelixis, Inc. | 139.60M |
| United Therapeutics Corp. | 156.60M |